{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:58:06Z","timestamp":1793656686597,"version":"4.5.1"},"reference-count":21,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"Importance<\/jats:title>Patients with heart failure (HF) and mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF) have a spectrum of risk, and the effect of therapies may vary by risk.<\/jats:p><\/jats:sec>Objectives<\/jats:title>To validate the Prognostic Models for Mortality and Morbidity in HFpEF (PREDICT-HFpEF) in the phase 3 randomized clinical trial Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF) and to evaluate the effect of finerenone, compared with placebo, across the spectrum of risk in these patients.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>The FINEARTS-HF trial was conducted across 653 sites in 37 countries. Participants were adults 40 years and older with symptomatic HF and left ventricular EF of 40% or greater randomized between September 2020 and January 2023.<\/jats:p><\/jats:sec>Intervention<\/jats:title>Finerenone (titrated to 20 mg or 40 mg) or placebo.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The 3 PREDICT-HFpEF risk scores for the composite outcome of cardiovascular death or HF hospitalization, cardiovascular death, and all-cause death, respectively, were calculated. Predicted risk was compared with observed outcomes. Model performance was assessed using the Harrell C statistic. The rates of the predicted outcomes (plus the composite of cardiovascular death and worsening HF events, which was the primary end point in the trial) were examined according to quintiles of risk score, as was the effect of finerenone according to risk quintiles.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 6001 patients (mean [SD] age, 72 [9.6] years; 3269 male [54.5%]) were randomized in the FINEARTS-HF trial. The C statistics for cardiovascular death or HF hospitalization, cardiovascular death, and all-cause death at 2 years were 0.71 (95% CI, 0.69-0.72), 0.68 (95% CI, 0.66-0.71), and 0.69 (95% CI, 0.67-0.71), respectively. The risk of the composite outcomes was approximately 8- to 10-fold higher in those in the highest compared with the lowest risk quintile. The relative risk reduction with finerenone compared with placebo was consistent across the spectrum of risk for all outcomes examined (eg, interaction P<\/jats:italic> value for primary outcome\u2009=\u2009.24).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Results of the FINEARTS-HF randomized clinical trial demonstrate that the PREDICT-HFpEF models performed well in terms of calibration and discrimination. Baseline risk did not modify the benefit of finerenone.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT04435626<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2025.0025","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:01:48Z","timestamp":1741190508000},"page":"535","source":"Crossref","is-referenced-by-count":11,"title":["Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model"],"prefix":"10.1001","volume":"10","author":[{"given":"Kirsty","family":"McDowell","sequence":"first","affiliation":[{"name":"School of Cardiovascular & Metabolic Health, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran F.","family":"Docherty","sequence":"additional","affiliation":[{"name":"School of Cardiovascular & Metabolic Health, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross T.","family":"Campbell","sequence":"additional","affiliation":[{"name":"School of Cardiovascular & Metabolic Health, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alasdair D.","family":"Henderson","sequence":"additional","affiliation":[{"name":"School of Cardiovascular & Metabolic Health, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[{"name":"School of Cardiovascular & Metabolic Health, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lay-Flurrie","sequence":"additional","affiliation":[{"name":"Bayer PLC, Research & Development, Pharmaceuticals, Reading, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Hofmeister","sequence":"additional","affiliation":[{"name":"Bayer AG, Global Medical Affairs, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Scalise","sequence":"additional","affiliation":[{"name":"Cardiology and Nephrology Clinical Development, Bayer Hispania S.L., Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S. P.","family":"Lam","sequence":"additional","affiliation":[{"name":"National Heart Centre Singapore & Duke-National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Petrie","sequence":"additional","affiliation":[{"name":"School of Cardiovascular & Metabolic Health, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Schou","sequence":"additional","affiliation":[{"name":"Herlev-Gentofte University Hospital, Hellerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Senni","sequence":"additional","affiliation":[{"name":"University of Milano-Bicocca ASST Papa Giovanni XXIII Hospital, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv J.","family":"Shah","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob A.","family":"Udell","sequence":"additional","affiliation":[{"name":"Women\u2019s College Hospital and Peter Munk Cardiac Centre, Toronto General Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"University of Lorraine, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"School of Cardiovascular & Metabolic Health, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"hoi250002r1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCHEARTFAILURE.111.965848","article-title":"Heart failure prognostic models: why bother?","volume":"5","author":"Aaronson","year":"2012","journal-title":"Circ Heart Fail"},{"issue":"21","key":"hoi250002r2","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1001\/jama.299.21.2533","article-title":"Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure.","volume":"299","author":"Allen","year":"2008","journal-title":"JAMA"},{"issue":"4","key":"hoi250002r3","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/hrt.2006.089656","article-title":"Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure.","volume":"93","author":"Raphael","year":"2007","journal-title":"Heart"},{"issue":"6","key":"hoi250002r4","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/01.CIR.64.6.1227","article-title":"Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale.","volume":"64","author":"Goldman","year":"1981","journal-title":"Circulation"},{"key":"hoi250002r5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.hrtlng.2021.07.009","article-title":"Providers\u2019 assignment of NYHA functional class in patients with heart failure: a vignette study.","volume":"51","author":"Stamp","year":"2022","journal-title":"Heart Lung"},{"issue":"2","key":"hoi250002r6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1001\/jamacardio.2022.4427","article-title":"Associations between New York Heart Association classification, objective measures, and long-term prognosis in mild heart failure: a secondary analysis of the PARADIGM-HF trial.","volume":"8","author":"Rohde","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"1","key":"hoi250002r7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/eurheartj\/ehi555","article-title":"Predictors of mortality and morbidity in patients with chronic heart failure.","volume":"27","author":"Pocock","year":"2006","journal-title":"Eur Heart J"},{"issue":"20","key":"hoi250002r8","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009594","article-title":"Meta-Analysis Global Group in Chronic (MAGGIC) heart failure risk score: validation of a simple tool for the prediction of morbidity and mortality in heart failure with preserved ejection fraction.","volume":"7","author":"Rich","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"hoi250002r9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1161\/CIRCHEARTFAILURE.109.932996","article-title":"Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE).","volume":"4","author":"Komajda","year":"2011","journal-title":"Circ Heart Fail"},{"key":"hoi250002r10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ijcard.2018.10.076","article-title":"The 3A3B score: the simple risk score for heart failure with preserved ejection fraction\u2014a report from the CHART-2 study.","volume":"284","author":"Kasahara","year":"2019","journal-title":"Int J Cardiol"},{"issue":"10","key":"hoi250002r11","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1002\/ejhf.2607","article-title":"Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.","volume":"24","author":"Pocock","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"hoi250002r12","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.urolonc.2004.04.012","article-title":"Incorporating predictions of individual patient risk in clinical trials.","volume":"22","author":"Kattan","year":"2004","journal-title":"Urol Oncol"},{"issue":"5","key":"hoi250002r13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1001\/jamacardio.2024.0284","article-title":"Prognostic models for mortality and morbidity in heart failure with preserved ejection fraction.","volume":"9","author":"McDowell","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"12","key":"hoi250002r14","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"17","key":"hoi250002r15","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction.","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"issue":"23","key":"hoi250002r16","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction.","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"issue":"16","key":"hoi250002r17","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction.","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"hoi250002r18","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/ejhf.3266","article-title":"Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: the FINEARTS-HF trial.","volume":"26","author":"Solomon","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"hoi250002r19","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/ejhf.3253","article-title":"Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: rationale and design of the FINEARTS-HF trial.","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"hoi250002r20","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jacc.2024.09.004","article-title":"Finerenone in patients with a recent worsening heart failure event: the FINEARTS-HF trial.","volume":"85","author":"Desai","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"hoi250002r21","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jchf.2017.04.013","article-title":"Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial.","volume":"5","author":"Solomon","year":"2017","journal-title":"JACC Heart Fail"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2830951\/jamacardiology_mcdowell_2025_oi_250002_1749063415.37737.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T15:00:53Z","timestamp":1749654053000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2830951"}},"subtitle":["A Secondary Analysis of FINEARTS-HF"],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2025.0025","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}